CKU-24329-22723
3 vaccinations
1 coded response
9 check-ins
1 free-text entry
0 call cases
- Sex
- Female
- Age at first dose
- 31-35
- ZIP prefix
- 923 / CA
- Registered
- 2021-01-15
- Relationship
- Self
- Race
- Asian
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2021-01-14
Dose 1 — Pfizer-BioNTech
-
2021-01-15
Registered in v-safe
- 2021-01-15
- 2021-01-16
- 2021-01-17
-
2021-02-04
Dose 2 — Pfizer-BioNTech
- 2021-07-17
-
2021-12-17
Dose 3 — Pfizer-BioNTech
- 2022-01-14
- 2022-01-16
- 2022-01-21
-
2022-01-28
Survey response — day 42, dose 3MedDRA: Nasal congestion, Rhinorrhoea — Feeling: GoodFree text: Congested nostril and slight runny nose.MedDRA releases: 2024-11 · check-in free text available
- 2022-03-18
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-01-14 | Pfizer-BioNTech | |
| 2 | 2021-02-04 | Pfizer-BioNTech | No |
| 3 | 2021-12-17 | Pfizer-BioNTech | No |
Free text
Release 11 — day 42, dose 3
Symptoms: Congested nostril and slight runny nose.
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Nasal congestion | · | · | ✓ |
| SD | Rhinorrhoea | · | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release